Back to articles

New Hope Dawns: AI-Powered Precision Strikes Rare Ovarian Cancer

Benjamin Moore•May 20, 2025
An abstract image depicting a beacon of light piercing through darkness, intertwined with a subtle representation of a DNA strand and AI neural network pathways, symbolizing hope and precision in cancer treatment.
  • A revolutionary FDA-approved therapy, avutometinib plus defactinib, now offers a lifeline for women battling recurrent KRAS-mutant Low-Grade Serous Ovarian Cancer (LGSOC)8.
  • Tech pioneer Tempus AI joins forces with Verastem Oncology, deploying its cutting-edge xT CDx assay to guide this breakthrough treatment.
  • This collaboration heralds a new era of personalized medicine, targeting a devastating cancer that disproportionately affects younger women1,4.

For too long, women diagnosed with recurrent Low-Grade Serous Ovarian Cancer (LGSOC) faced a daunting prognosis—a rare, tenacious cancer with dismal response rates to conventional chemotherapy, often striking younger women1,4. But the landscape is dramatically shifting. The U.S. FDA has granted accelerated approval to a groundbreaking combination therapy from Verastem Oncology, avutometinib and defactinib, the first-ever specifically for KRAS-mutant recurrent LGSOC, based on the promising RAMP-201 trial which showed significant tumor reductions5,7,8.

At the heart of this medical advancement is a pivotal collaboration with Tempus AI. Leveraging its AI-powered xT CDx assay, Tempus is developing the essential companion diagnostic. This sophisticated test identifies the critical KRAS mutation, ensuring the right patients receive this targeted therapy. Already proven in confirmatory testing for RAMP-201, the assay is now integral to the global Phase 3 RAMP-301 trial1,2.

"We look forward to continuing to work with Verastem to pursue an unmet need," said Mike Yasiejko of Tempus. John Hayslip of Verastem hailed the collaboration as "a critical step in bringing targeted therapies to patients." This synergy isn't just advancing science; it’s delivering tangible hope and a powerful new weapon against a formidable disease, promising to transform outcomes for a historically underserved community3,6. Discover more at tempus.com.

References

  1. investors.tempus.com
  2. www.360dx.com
  3. in.investing.com
  4. www.streetinsider.com
  5. www.cancernetwork.com
  6. www.gurufocus.com
  7. investor.verastem.com
  8. ocrahope.org

Stay Updated!

Get the latest biotech and pharma news delivered to your inbox.